Outcome of the Board meeting and declaration of results for the quarter and nine months ending 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syschem India reported a sharp jump in Q3 FY26 (quarter ended 31 Dec 2025) revenue from operations at ₹16,164 lakhs, up about 77% from ₹9,113 lakhs in the same quarter last year. Nine-month revenue rose to ₹40,632 lakhs versus ₹24,748 lakhs last year, already exceeding the full FY25 revenue of ₹38,623 lakhs. Profit after tax for the quarter stood at ₹417 lakhs (vs ₹50 lakhs a year ago), and 9M PAT swung from a marginal loss to ₹774 lakhs. The statutory auditors (Stav & Co) issued an unmodified limited review report with no qualifications. The Board also approved a revised Related Party Transactions policy to align with the latest SEBI circular, and cleared a ₹14 crore expansion of its Panchkula plant — adding new Amoxicillin and Ampicillin capacity, expanding the existing CDF (Cloxacillin/Dicloxacillin/Flucloxacillin) unit, and upgrading effluent treatment systems — to be funded via internal accruals and borrowings, with commissioning targeted by December 2026.
Strong revenue and profit growth, along with a clean auditor report and a capex-led capacity expansion, are positive signals for shareholders. The stock could see upward momentum, though the ₹14 crore expansion funded partly through borrowings warrants a watch on debt levels going forward.